These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Isoniazid induced motor-dominant neuropathy. Arsalan R, Sabzwari S. J Pak Med Assoc; 2015 Oct; 65(10):1131-3. PubMed ID: 26440850 [Abstract] [Full Text] [Related]
3. Exacerbation of isoniazid induced peripheral neuropathy by pyridoxine. Nisar M, Watkin SW, Bucknall RC, Agnew RA. Thorax; 1990 May; 45(5):419-20. PubMed ID: 2166360 [Abstract] [Full Text] [Related]
4. Should we ban B6 supplementation of INH therapy in childhood tuberculosis? Mathur GP, Mathur S, Rastogi S. Indian J Pediatr; 1993 May; 60(6):717-9. PubMed ID: 8200694 [No Abstract] [Full Text] [Related]
5. Peripheral neuropathy secondary to isoniazid-induced pyridoxine deficiency. Aita JF, Calame TR. Md State Med J; 1972 Oct; 21(10):68-70. PubMed ID: 4353461 [No Abstract] [Full Text] [Related]
7. [Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)]. Musch E, Eichelbaum M, Wang JK, von Sassen W, Castro-Parra M, Dengler HJ. Klin Wochenschr; 1982 May 17; 60(10):513-9. PubMed ID: 7098379 [Abstract] [Full Text] [Related]
8. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, Barry MA, O'Brien RJ. JAMA; 2000 Mar 15; 283(11):1445-50. PubMed ID: 10732934 [Abstract] [Full Text] [Related]
10. Acetylator phenotype and short-course chemotherapy for tuberculosis in Papua New Guinea. Currie B, Krause V, Mondia P, Hudson B. P N G Med J; 1989 Dec 15; 32(4):259-62. PubMed ID: 2560598 [Abstract] [Full Text] [Related]
12. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society. Monaldi Arch Chest Dis; 1994 Sep 15; 49(4):327-45. PubMed ID: 8000420 [Abstract] [Full Text] [Related]
13. Isoniazid induced early-onset of motor dominant neuropathy and treatment with high dose of pyridoxine. Choudhary CR, Kumari J, Advani M. Indian J Tuberc; 2018 Apr 15; 65(2):175-176. PubMed ID: 29579435 [No Abstract] [Full Text] [Related]
17. Impact of the Increased Recommended Dosage of Isoniazid on Pyridoxine Levels in Children and Adolescents. Rodà D, Rozas L, Fortuny C, Sierra C, Noguera-Julian A. Pediatr Infect Dis J; 2016 May 15; 35(5):586-9. PubMed ID: 26862674 [Abstract] [Full Text] [Related]
19. Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy. Sundell J, Bienvenu E, Janzén D, Birgersson S, Äbelö A, Ashton M. Clin Pharmacol Ther; 2020 Jul 15; 108(1):73-80. PubMed ID: 32017035 [Abstract] [Full Text] [Related]